The Heart Valve Society meeting in Chicago this week brought together surgeons, cardiologists, and researchers from across the world to exchange ideas and recent findings. Much of the discussion centered on how rapidly transcatheter therapies are reshaping the treatment landscape. Several speakers emphasized that minimally invasive approaches are no longer niche options but are becoming standard in selected patient groups. There was a strong focus on patient selection, highlighting that good outcomes depend as much on judgment as on technology. New data on long-term durability of transcatheter valves drew considerable attention and cautious optimism. At the same time, presenters reminded the audience that surgical repair still remains the gold standard for many conditions, especially in younger patients.

Another recurring theme was the importance of multidisciplinary heart teams in decision-making. Speakers stressed that collaboration between imaging specialists, surgeons, and interventional cardiologists leads to better individualized care. Advances in imaging, particularly 3D and real-time modalities, were showcased as key tools for procedural planning. There was also discussion about expanding indications for earlier intervention before symptoms become severe. Some talks addressed disparities in access to advanced valve therapies and the need to close those gaps.

Innovation was clearly a forward-looking pillar of the meeting, with early-stage devices and techniques presented in preview sessions. However, caution was urged to balance enthusiasm with rigorous clinical evidence. Training the next generation of specialists came up frequently, especially as procedures become more technically complex. There was a sense that education needs to evolve alongside the technology.

Another message that stood out was the growing role of data registries and real-world evidence in shaping guidelines. Speakers pointed out that randomized trials alone cannot answer every practical question clinicians face. The integration of artificial intelligence into diagnostics and procedural planning was also discussed as an emerging frontier. Still, many emphasized that human expertise remains irreplaceable in interpreting complex cases.

Looking ahead, the tone of the meeting suggested steady progress rather than sudden disruption. The field appears to be moving toward more personalized, less invasive, and more data-driven care. At the same time, there was a clear recognition that durability, cost, and equitable access will define the next phase of development. Overall, the meeting conveyed cautious confidence that heart valve treatment will continue to improve, provided innovation is matched with thoughtful clinical application.

Author of this article

Borut Gersak, MD, PhD

Specialty: Cardiovascular Surgery

He is a Professor of Surgery at the Faculty of Medicine, University of Ljubljana in Slovenia, and is affiliated with the Department of Cardiovascular Surgery at the University Medical Center Ljubljana.
With over 35 years of experience in the field of cardiovascular medicine, he has authored and presented more than 500 peer-reviewed papers and conference presentations on a wide range of topics in cardiac surgery.
He is currently particularly active in the United States and Japan.

View all articles

Author Profile

Tokyo D Tower Hospital – Overview

advanced medical equipment

all-private rooms

〒135−0061
1st Floor & 3rd–5th Floors, D Tower Toyosu, 6-4-20 Toyosu, Koto-ku, Tokyo, Japan
TEL：03−6910−1722
ACCESS：A 2-minute walk from Shijō-mae Station (Yurikamome Line)

Neurosurgery, Cardiology, Cardiovascular Surgery, Orthopedic Surgery, Endocrinology, and Health Checkups and Specialized Screening Programs

Click here for a free email consultation